The fund's primary objective is to achieve long-term capital appreciation. To meet this goal, it typically invests at least 80% of its net assets (including any assets acquired through borrowing) in the common stocks of companies within the broad "health sciences" sector. This includes firms involved in the research, development, production, or distribution of products and services related to healthcare, medicine, or life sciences.
